Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.67 |
| ▸ | FNTB | P49356 | 16/20 | 0.67 |
| ▸ | PGGT1B | P53609 | 12/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16136603 | 1.00 | FNTA (0.67) | FNTAFNTBPGGT1BCA2CA1 | |
| SCHEMBL10038916 | 1.00 | FNTA (0.67) | FNTAFNTBPGGT1BCA2CA1 | |
| SCHEMBL25722631 | 0.89 | FNTA (0.64) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL17547687 | 0.87 | FNTA (0.52) | FNTAFNTBPGGT1BCA2CA1 | |
| SCHEMBL10038922 | 0.85 | FNTA (0.78) | FNTAFNTBPGGT1BCA2CA1 | |
| Cysteine SCHEMBL8365455 | 0.83 | CA2 (0.60) | FNTAFNTBPGGT1BCA2CA1 | |
| SCHEMBL8368433 | 0.82 | FNTA (0.69) | FNTAFNTBPGGT1BCA2CA1 | |
| SCHEMBL8750233 | 0.80 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL2543348 | 0.79 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL27799999 | 0.79 | FNTA (0.67) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | disclosed |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | disclosed |
| US-6011175-A | Inhibition of farnesyltransferase | UNIVERSITY OF PITTSBURGH (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0794789-A4 | INHIBITORS OF PRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-05-26 | — | — | EP | disclosed |
| EP-0794789-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | FNTA 874/4885FNTB 1328/4885PGGT1B 939/4885 |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | FNTA 1114/4885FNTB 1259/4885PGGT1B 2389/4885 |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | FNTA 1/4885FNTB 3/4885PGGT1B 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.